Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The level of Galectin-3 (Gal-3) protein purportedly reflects an ongoing cardiac fibrotic process and has been associated with ventricular remodeling, which is instrumental in the development of heart failure with preserved ejection fraction (HFpEF) syndrome. The aim of this study was to investigate the potential use of Gal-3 in improved characterization of the grades of diastolic dysfunction as defined by echocardiography. Methods: Seventy HFpEF patients undergoing routine echocardiography were prospectively enrolled in the present monocentric study. Blood samples for measurements of Gal-3 and amino-terminal pro-brain natriuretic peptide (NT-proBNP) were collected within 24 hours pre- or post-echocardiographic examination. The classification of patients into subgroups based on diastolic dysfunction grade permitted detailed statistical analyses of the derived data. Results: The Gal-3 serum levels of all patients corresponded to echocardiographic indices, suggesting HFpEF (E/A, P =0.03 and E/E’, P =0.02). Gal-3 was also associated with progressive diastolic dysfunction, and increased levels corresponded to the course of disease (P =0.012). Detailed analyses of ROC curves suggested that Gal-3 levels could discriminate patients with grade III diastolic dysfunction (area under the curve [AUC]=0.770, P =0.005). Conclusions: Gal-3 demonstrates remarkable effectiveness in the diagnosis of patients suffering from severe grade diastolic dysfunction. Increasing levels of Gal-3 possibly reflect the progressive course of HFpEF, as classified by the echocardiographic grades of diastolic dysfunction.
Abstract
Background: The level of Galectin-3 (Gal-3) protein purportedly reflects an ongoing cardiac fibrotic process and has been associated with ventricular remodeling, which is instrumental in the development of heart failure with preserved ejection fraction (HFpEF) syndrome. The aim of this study was to investigate the potential use of Gal-3 in improved characterization of the grades of diastolic dysfunction as defined by echocardiography. Methods: Seventy HFpEF patients undergoing routine echocardiography were prospectively enrolled in the present monocentric study. Blood samples for measurements of Gal-3 and amino-terminal pro-brain natriuretic peptide (NT-proBNP) were collected within 24 hours pre- or post-echocardiographic examination. The classification of patients into subgroups based on diastolic dysfunction grade permitted detailed statistical analyses of the derived data. Results: The Gal-3 serum levels of all patients corresponded to echocardiographic indices, suggesting HFpEF (E/A, P =0.03 and E/E’, P =0.02). Gal-3 was also associated with progressive diastolic dysfunction, and increased levels corresponded to the course of disease (P =0.012). Detailed analyses of ROC curves suggested that Gal-3 levels could discriminate patients with grade III diastolic dysfunction (area under the curve [AUC]=0.770, P =0.005). Conclusions: Gal-3 demonstrates remarkable effectiveness in the diagnosis of patients suffering from severe grade diastolic dysfunction. Increasing levels of Gal-3 possibly reflect the progressive course of HFpEF, as classified by the echocardiographic grades of diastolic dysfunction.
참고문헌 (34)
- Go AS, "Heart disease and stroke statistics--2014 update: a report from the American Heart Association", Circulation, 129, pp.28~292 (2014)[DOI]
- McMurray JJ, "ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC", Eur Heart J, 33, pp.1787~1847 (2012)[DOI]
- Cheng JM, "Biomarkers of heart failure with normal ejection fraction: a systematic review", Eur J Heart Fail, 15, pp.1350~1362 (2013)[DOI]
- de Boer RA, "Galectin-3 in heart failure with preserved ejection fraction", Eur J Heart Fail, 15, pp.1095~1101 (2013)[DOI]
- Tribouilloy C, "Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study", Eur Heart J, 29, pp.339~347 (2008)[DOI]
- Gonzalez A, "Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system", Med Clin North Am, 88, pp.83~97 (2004)[DOI]
- Mitchell JA, "Early recognition and treatment of hypertensive heart disease", Curr Opin Cardiol, 20, pp.282~289 (2005)[DOI]
- de Boer RA, "The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities", Microcirculation, 10, pp.113~126 (2003)[DOI]
- Henderson NC, "The regulation of inflammation by Galectin-3", Immunol Rev, 230, pp.160~171 (2009)[DOI]
- Reifenberg K, "Interferon-<TEX>${\gamma}$<", TEX> induces chronic active myocarditis and cardiomyopathy in transgenic mice, 2007, pp.171, 463~472
- Lok DJ, "Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study", Clin Res Cardiol, 99, pp.323~328 (2010)[DOI]
- Shah RV, "Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure", Eur J Heart Fail, 12, pp.826~832 (2010)[DOI]
- Nagueh SF, "Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", J Am Soc Echocardiogr, 29, pp.277~314 (2016)[DOI]
- Penicka M, "Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography", Heart, 100, pp.68~76 (2014)[DOI]
- Gruson D, "Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failure", Clin Biochem, 47, pp.1006~1009 (2014)[DOI]
- Carrasco-Sanchez FJ, "Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction", Int J Cardiol, 169, pp.177~182 (2013)[DOI]
- de Boer RA, "Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction", Ann Med, 43, pp.60~68 (2011)[DOI]
- Zile MR, "Plasma galectin-3 levels in patients with structural and clinical manifestation of hypertensive heart disease: relationship to determination of matrix composition", Circulation, 122(S1), pp.A12433~ (2010)
- Sharma UC, "Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction", Circulation, 110, pp.3121~3128 (2004)[DOI]
- Liu YH, "Nacetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion", growth-regulatory lectin, 2009, pp.296, 404~412
- de Boer RA, "Galectin-3: a novel mediator of heart failure development and progression", Eur J Heart Fail, 11, pp.811~817 (2009)[DOI]
- van Kimmenade RR, "Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure", J Am Coll Cardiol, 48, pp.1217~1224 (2006)[DOI]
- Ho JE, "Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community", J Am Coll Cardiol, 60, pp.1249~1256 (2012)[DOI]
- de Boer RA, "The fibrosis marker galectin-3 and outcome in the general population", J Intern Med, 272, pp.55~64 (2012)[DOI]
- Edelmann F, "Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial", Eur J Heart Fail, 17, pp.214~223 (2015)[DOI]
- deFilippi CR, "Evolving role of galectin-3 as a cardiac biomarker. Heart failure with preserved ejection fraction and renal function, important pieces of the puzzle", JACC Heart Fail, 3, pp.253~256 (2015)[DOI]
- AbouEzzeddine OF, "Galectin-3 in heart failure with preserved ejection fraction: a RELAX trial substudy (phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure)", JACC Heart Fail, 3, pp.245~252 (2015)[DOI]
- Gopal DM, "Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure", J Am Heart Assoc, 1, pp.e000760~ (2012)
- Gurel OM, "Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients", Herz, 40, pp.788~794 (2015)[DOI]
- Smilde TD, "Differential associations between renal function and ''modifiable'' risk factors in patients with chronic heart failure", Clin Res Cardiol, 98, pp.121~129 (2009)[DOI]
- Bosnjak I, "Prognostic value of galectin-3 in patients with heart failure", Dis Markers, 2015, pp.690205~ (2015)
- Christenson RH, "Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure", Clin Biochem, 43, pp.683~690 (2010)[DOI]
- Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2013, 62[DOI]
- Van der Velde A, "Prognostic Value of Changes in Galectin-3 levels over time in Patients with Heart failure. Clinical Perspective Data from CORONA and COACH", Circulation: Heart Failure, 6, pp.219~226 (2013)[DOI]